| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8218115 | International Journal of Radiation Oncology*Biology*Physics | 2014 | 6 Pages |
Abstract
Patients enrolled in this trial had improved OS compared with poor-PS historical controls (10.5 vs 6.4Â months) and comparable OS to good-PS historical controls (10.5 vs 11.9Â months) treated with XRT alone. However, pulmonary toxicity is a concern. Consolidative cetuximab/docetaxel, in conjunction with high-dose radiation therapy, is a putative cause.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Thomas J. MD, Martine MD, Jongphil PhD, Lora M. PhD, Binglin MS, Craig W. MD, PhD, Scott MD, Jhanelle MD, Charles MD, Eric MD, Mary MD, Tawee MD, Sungjune MD, PhD, Alberto MD,